ARTL Stock Forecast: Artelo Biosciences, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$1.39

Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 24 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$1.4M
Ticker Nerd rank
24/ 100
Median analyst target
—
Analysts covering
—
Revenue$0.0
Operating income−$2.5M
Net income−$2.4M
Free cash flow−$5.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Artelo Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
24/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
87
Volatility
60
Issuance
49
Momentum
29
Revisions
20
Quality
14
Accruals
12
Value
10

Growth (87): Sales and profits are climbing, and climbing faster than before.

Value (10): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ARTL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ARTL, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
19 Nov 2025Maxim GroupDowngradeHold—
8 Sept 2025D. Boral CapitalDowngradeHold—
26 Aug 2025D. Boral CapitalMaintainsBuy—
18 Aug 2025D. Boral CapitalMaintainsBuy—
6 Aug 2025D. Boral CapitalMaintainsBuy—
4 Aug 2025D. Boral CapitalMaintainsBuy—
8 July 2025D. Boral CapitalUpgradeBuy—
11 June 2025D. Boral CapitalDowngradeHold—
6 June 2025D. Boral CapitalMaintainsBuy—
28 Apr 2025D. Boral CapitalMaintainsBuy—
2 Apr 2025D. Boral CapitalMaintainsBuy—
4 Mar 2025HC Wainwright & Co.ReiteratesBuy—
3 Mar 2025D. Boral CapitalMaintainsBuy—
27 Feb 2025D. Boral CapitalMaintainsBuy—
14 Jan 2025D. Boral CapitalMaintainsBuy—
9 Dec 2024D. Boral CapitalMaintainsBuy—
9 Dec 2024HC Wainwright & Co.ReiteratesBuy—
13 Nov 2024HC Wainwright & Co.ReiteratesBuy$5.00
1 Oct 2024EF HuttonInitiatesBuy$6.00
14 Aug 2024HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

ARTL appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Estimates

ARTL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
0.7×

Cheaper than 80% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−404.0%

Higher than 3% of US stocks

Return on assets
−111.6%

Higher than 2% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Artelo Biosciences, Inc. has a market value of $1.4M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$12.7M.

  • Free cash flow in the twelve months to 30 June 2026: −$12.6M.

  • Shares outstanding: 3.5M.

  • Artelo Biosciences, Inc. employs 7 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

ARTL and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ARTLArtelo Biosciences, Inc.$1.4M24
ELABPMGC Holdings, Inc.$1.3M3
CMNDClearmind Medicine, Inc.$1.3M6
APVOAptevo Therapeutics, Inc.$1.4M29
BRTXBioRestorative Therapies, Inc.$1.4M6
ENLVEnlivex Ltd.$1.6M4
JUNSJupiter Neurosciences, Inc.$1.6M14

Take a look at ARTL’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Artelo Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about ARTL

How does Ticker Nerd's model rank ARTL?

As at 21 Nov 2026, Artelo Biosciences, Inc. ranks 24 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (87 of 100).

What is the ARTL stock forecast for 2030?

No analyst covering Artelo Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ARTL are extrapolating price history, which says nothing about the business.

What does Artelo Biosciences, Inc. do?

Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing proprietary therapeutics that modulate lipid-signaling pathways. Artelo Biosciences concentrates on treatments for conditions with significant unmet medical needs, including cancer-related anorexia, pain, inflammation, anxiety, dermatologic disorders, and other serious diseases.

Company

About Artelo Biosciences, Inc.

Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing proprietary therapeutics that modulate lipid-signaling pathways. Artelo Biosciences concentrates on treatments for conditions with significant unmet medical needs, including cancer-related anorexia, pain, inflammation, anxiety, dermatologic disorders, and other serious diseases. Its current pipeline includes product candidates such as ART27.13, ART12.11, and ART26.12, which are being developed across multiple therapeutic areas with an emphasis on endocannabinoid and fatty acid binding protein biology. The company’s work centers on advancing novel small-molecule and cannabinoid-based approaches aimed at improving care in oncology, neurology, and related fields. Artelo Biosciences is headquartered in Solana Beach, California, and operates as a research-driven company within the broader pharmaceutical market.

CEO Mr. Gregory D. Gorgas M.B.A. · 7 employees · United States · https://artelobio.com